The longest RCT follow-up data extend to roughly 2-3 years, creating genuine uncertainty about 5+ year outcomes including cardiovascular mortality, fracture risk, and rare malignancies like gallbladder cancer, which showed numerically higher risk in trials exceeding 104 weeks though with small event counts.
Evidence (2)
The expanding role of GLP-1 receptor agonists: a narrative review
Long-term safety beyond current trial durations remains an important open question.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00295-0/fulltext
GLP-1 receptor agonists for obesity: Growing popularity met with growing questions over safety
2026 Perspective arguing rising use demands better oversight and long-term monitoring.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12803457/
Respond to this claim on Isonomia
Build or challenge arguments with structured reasoning in the Digital Agora.